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  The isoflavonol glycoside Talosin A, genistein (GT)-7-α-L-6- 
deoxy talopyranose (GT-Tal), was first isolated from the 
culture broth of Kitasatospora kifunensis MJM341. The aim 
of the present study was to evaluate the oral absorption and 
metabolism of the newly isolated isoflavonol glycoside, GT-Tal 
compared to genistin (GT-7-O-β-D-glucopyranoside; GT- 
Glu). Free GT-Glu and GT-Tal could not be detected prior 
to enzymatic hydrolysis of the corresponding conjugates in 
rat plasma. Following oral administration of GT-Tal (15 min), 
GT-Tal was rapidly absorbed through the gastrointestinal 
tract and metabolized into GT-Tal conjugates with a mean 
Cmax of 2.74 μg/mL. GT-Tal was further metabolized to its 
aglycone, free GT and conjugated GT. After oral administration, 
GT-Glu was absorbed after being convereted to its aglycone 
and then further metabolized into its conjugate metabolites 
(free GT with a mean Cmax of 0.24 mg/mL at 1.25 h; conjugated 
GT with a mean Cmax of 1.31 mg/mL at 2.00 h). Significant 
differences in absorption and metabolism of GT-Tal and 
GT-Glu were observed. GT-Tal was metabolized into its 
corresponding conjugates or underwent deglycosylation to 
form GT, whereas GT-Glu was metabolized into its aglycone, 
GT. 
Keywords: genistin, isoflavonol, metabolism, pharmacokinetics, 
Talosin A
Introduction 
Isoflavones, major dietary components of soybeans, have 
received much attention because of their health-related and 
clinical benefits such as estrogenic and anti-oxidative 
activities as well as promoting natural killer cell activity 
[1,21,23]. In soybeans and soy-derived foods, genistein 
(GT; 4’,5,7-trihydroxy-isoflavone) is mainly present as a 
glycoside, genistin (GT-7-O-β-D-glucopyranoside, GT- 
Glu). It is well-known that colonic bacteria convert 
GT-Glu into the corresponding aglycone, GT [1,11,21,23].
A large number of novel bioactive metabolites are derived 
from actinomycetes [10]. The genus Kitasatospora was 
first identified by Omura et al. [12] as an actinomycete 
with the unique characteristic of containing meso- and 
LL-diaminopimelic acid as diamino acid in the cell wall. 
Several Kitasatospora species have been reported to be 
producers of novel bioactive compounds with varying 
structures and beneficial functions including antifungal 
activity, antitumor activity, immunomodulation, and 
proteinase inhibition [10,12,18]. 
Talosin A, GT-7-α-L-6-deoxy talopyranose (GT-Tal), is a 
new isoflavonol glycoside that was first isolated from the 
culture broth of Kitasatospora kifunensis MJM341 [7,22]. 
Soy isoflavones are composed of GT, daidzein, and, to a 
lesser extent, glycitein. Their biological effects are a topic 
of considerable current interest due to their health-related 
and clinical benefits such as estrogenic and anti-oxidative 
activities [4,6,23]. Unlike other isoflavones, GT-Tal has a 
strong antifungal activity against Candida albicans, 
Aspergillus niger, and Cryptococcus neoformans [22]. 
Moreover, our previous study showed that GT-Tal may 
exert potent anti-inflammatory effects such as the 
inhibition of nuclear factor-κB activation, the production 
of nitric oxide (NO), and the production of pro- 
inflammatory cytokines [5]. Understanding the in vivo 
pharmacokinetics and metabolism of GT-Tal is essential 
for the biomedical applications of this compound. It is 
currently unknown whether GT-Tal can be absorbed in its 
intact form or is hydrolyzed into its aglycone form during 
the absorption process. Moreover, there are no previous 
studies that describe a method for analyzing GT-Tal in 
biological fluids. Therefore, this study evaluated the 116    Jong-Hwan Lim et al.
pharmacokinetics and metabolism of GT-Tal in rats 
following oral administration of this compound.
Materials and Methods
Chemicals
GT and GT-Glu were purchased from Sigma (USA) and 
LC Laboratories (USA), respectively. Formononetin 
(Sigma, USA) served as an internal standard (IS). Methyl 
tetra-butyl ether (MTBE), dimethyl sulfoxide (DMSO), 
acetic acid and ammonium acetate were reagent grade and 
purchased from Sigma (USA). Hydrolytic enzyme such as 
α-glucosidase,  β-glucosidase,  β-glucuronidase/sulfatase 
from Helix pomatia and sulfatase from Helix pomatia were 
also purchased from Sigma (USA). HPLC grade methanol 
and acetonitrile were purchased from Mallinckrodt Baker 
(USA).
Bacterial strain and preparation of GT-Tal
Kitasatospora kifunensis MJM341 was isolated from a 
soil sample collected in Gyeonggi province, Korea [7]. For 
the production of GT-Tal, Kitasatospora kifunensis MJM341 
was incubated in a 2 L baffled flask containing 500 mL of 
glucose soluble starch medium for 6 days at 28
oC on a 
rotary shaker at 200 rpm. For the purification of GT-Tal, 
the supernatant was extracted from the culture broth with 
butanol (1：1, v:v) and oily materials were delipidated by 
partitioning with n-hexane and 15% methanol. The 
aqueous methanol layer was separated using C18 reversed- 
phase vacuum flash column chromatography with 
sequential mixtures of MeOH from 0 to 100%. The fraction 
eluted with 20% aqueous MeOH was further separated by 
a C18 reversed-phase column (semi- preparative Symmetry 
RP-18 column, 10 μm, 7.8 × 300 mm; Waters, USA) to 
recover the GT-Tal. The mobile phase consisted of a 
mixture of acetonitril and water (28：72, v:v). The flow 
rate was set at 4 mL/min with an injection volume of 500 
μL. 
Animals and sample collections
The experimental protocols were approved by the 
Institutional Animal Care and Use Committee of Chungnam 
National University (Korea). Male Sprague-Dawley rats 
weighing between 160 and 220 g at the age of 6∼7 weeks 
were used for this study. The animals were obtained from 
Samtako Biokorea (Korea) and acclimated for 1 week 
before the experiments. The rats were randomly divided 
into two groups of four male rats each. Oral doses of 
GT-Glu and GT-Tal were administered by oral gavage in a 
50% DMSO solution at 20 mg/kg of bodyweight. Blood 
samples (0.2 mL each) were collected from the tail vein at 
the predetermined time points (pre-dosing and 0.25, 0.5, 1, 
2, 4, 6, 8, 12, and 24 h after dosing). The collected blood 
samples were centrifuged at 6,000 rpm for 10 min. 
Separated plasma was immediately stored at −40
oC until 
further use. 
Hydrolysis experiments
Various forms of hydrolytic enzymes including α- 
glucosidase (5 U), β-glucosidase (5 U), β-glucuronidase/ 
sulfatase (10 U) and sulfatase (10 U) were used in a pilot 
study to determine which enzyme hydrolyzed 6-deoxy- 
L-talopyranose or D-glucopyranoside. Each enzyme was 
added to a 500 μL solution containing 5 μg/mL of GT-Tal 
and GT-Glu at 37
oC. The reaction was allowed to proceed 
for 0.5, 1, 2, 4, 6, and 8 h and stopped by the addition of 200 
μL of acetonitrile containing ascorbic acid. Each sample 
was then analyzed by liquid chromatography/mass 
spectrometry (LC/MS, Agilent, USA). 
Sample  preparation  and  determination  of  GT, 
GT-Glu and GT-Tal 
For the quantification of total plasma GT or GT-Tal 
(conjugated + unconjugated forms), 50 μL of plasma 
samples and 10 μL of IS were incubated overnight at at 
37
oC in 0.17 M ammonium acetate (pH 4.6) containing 
1,000 U of β-glucuronidase/sulfatase from Helix pomatia 
(final volume 600 μL) to hydrolyze the conjugates. The 
reaction was stopped by adding a 4-fold volume of MTBE 
and then centrifuged at 1,200 ×g for 15 min. The supernatant 
was transferred into another tube and evaporated at 30
oC 
under a stream of nitrogen. The residue was reconstituted 
with a mobile phase. Preliminary studies and the hydrolysis 
experiments in the present study showed that this protocol 
results in the complete hydrolyzation of conjugated GT or 
GT-Tal [9,15,24]. For the quantification of free GT, 
GT-Glu, or GT-Tal (unconjugated forms) plasma 
concentration, thawed plasma samples were extracted as 
described above without prior enzymatic hydrolysis. The 
amount of conjugated GT or GT-Tal in plasma was 
calculated as the difference between total GT or GT-Tal 
and free GT or GT-Tal.
　Extracted plasma samples were analyzed on the Agilent 
1100 series LC/MS system (USA). Separation was 
achieved using the Zorbax Extended C18 reverse phase 
column (3.5 μm, 4.6 mm ×50 mm; Agilent, USA) and the 
mobile phase consisted of 35% 10 mM ammonium acetate 
(pH 4.0) and 65% acetonitrile. The flow rate was 0.4 
mL/min. The column effluent was introduced into the mass 
spectrometer using electrospray ionization. Mass 
spectrometry was performed using the positive ion mode 
and the selected ion monitoring, and detecting m/z 271 
(GT), 433 (GT-Glu), 417 (GT-Tal) and 269 (IS) with z peak 
width of 0.07 and dwell time of 197 ms. The lower limit of 
quantitation was 50 ng/mL for GT, GT-Glu, and GT-Tal. 
The intra- and inter-day variability for the entire standard 
curve was ∼14% for GT, ∼14% for GT-Glu, and ∼12% 
for GT-Tal.　Metabolism of Talosin A    117
Fig. 1. Mean plasma concentration-time curves of genistein (GT)
after an oral administration of 20 mg/kg GT-7-O-β-D- 
glucopyranoside (GT-Glu) in rats (n = 4). Filled circles (•): 
conjugated plasma GT, empty circles (◦): free plasma GT. Free
GT-Glu was not detected in rat plasma samples after oral 
administration of genistin. Data are expressed as mean ± SD.
Fig. 2. Mean plasma concentration-time curves of GT-7-α-L-6- 
deoxy talopyranose (GT-Tal) and GT after an oral administration
of 20 mg/kg GT-Tal in rats (n = 4). Filled circles (•): plasma 
conjugated GT-Tal, empty circles (◦): plasma conjugated GT, 
filled triangles (▾): free plasma GT. Free GT-Tal was not 
detected in rat plasma samples after oral administration of 
GT-Tal. Data are expressed as mean ± SD.
Table 1. Pharmacokinetic parameters of GT-Glu in rats after a 
single oral administration of GT-Glu 
Pharmacokinetic 
parameters*
Units
Compounds
Free GT Conjugated GT
λz 1/h 0.44 ± 0.15 0.06 ± 0.20
t1/2λZ h 1.58 ± 0.54 1.16 ± 0.40
Cmax μg/mL 0.24 ± 0.08 1.31 ± 0.45
Tmax h 1.25 ± 0.05 2.00 ± 0.00
AUC0-12 h h･μg/mL 1.10 ± 0.73 7.03 ± 1.91
AUC0-∞ h･μg/mL 1.16 ± 0.40 7.16 ± 1.90
MRT h 3.43 ± 0.66 4.11 ± 0.96
*λz: first order rate constant associated with the terminal (log-linear)
elimination phase, t1/2λZ: terminal half-life, Cmax: the peak or 
maximum concentration, Tmax: the time of peak concentration, 
AUC0-12 h: area under concentration curve (AUC) calculated from 
time zero to 12 h, AUC0-∞: AUC from time zero extrapolated to 
infinity, MRT: mean residual time. GT: genistein, GT-Glu: 
GT-7-O-β-D-glucopyranoside. Data are expressed as mean ± SD.
Pharmacokinetic analysis
GT or GT-Tal plasma concentrations versus time were 
analyzed by a non-compartmental analysis using 
WinNonlin 5.2 (Pharsight Corporation, USA). A non- 
compartmental analysis based on statistical moments was 
also performed. The area under the plasma concentration- 
time curve (AUC) and the area under the first moment 
curve (AUMC) were calculated by the method of trapezoids 
and extrapolation to infinity. The mean residence time 
(MRT) was determined by the formula: MRT = AUMC/ 
AUC. Peak plasma concentrations (Cmax) and times to 
reach peak concentration (tmax) after the oral administration 
were determined from the individual plasma concentration- 
time curves. 
Results 
Enzymatic hydrolysis
GT-Glu was quickly hydrolyzed enzymatically to its 
corresponding aglycon, GT, by α-glucosidase, β-glucosidase, 
β-glucuronidase/sulfatase, and sulfatase (data not shown). 
However, GT-Tal was not hydrolyzed to GT by these 
enzymes.
Oral absorption of genistin and GT-Tal
The plasma concentration-time profiles of total GT-Glu 
and GT-Tal after oral administration of GT-Glu and GT-Tal 
are shown in Figs. 1 and 2. The pharmacokinetic parameters 
for GT-Glu and GT-Tal are summarized in Tables 1 and 2. 
Free GT-Glu or GT-Tal could not be detected prior to 
enzymatic hydrolysis of the conjugates after oral 
administration. GT-Glu was slowly absorbed compared to 
GT-Tal after being converted into its aglycone and 
conjugate metabolites (Free-GT, Cmax of 0.24 ± 0.08 
μg/mL at 1.25 ± 0.05 h; Conjugated-GT, Cmax of 1.31 ± 
0.45 μg/mL at 2.00 ± 0.00 h; Table 1). GT-Tal was rapidly 
absorbed through the gastrointestinal tract and metabolized 
into conjugates of GT-Tal with a Cmax of 2.74 ± 0.93 μg/mL 
at 0.25 ± 0.00 h (Table 2). It was further metabolized into its 
aglycone, Free-GT, with a Cmax of 0.24 ± 0.01 μg/mL at 
1.00 ± 0.00 h and Conjugated-GT with a Cmax of 0.41 ± 0.25 
μg/mL at 0.69 ± 0.38 h (Table 2). 118    Jong-Hwan Lim et al.
Table 2. Pharmacokinetic parameters of GT-Tal in rats after a 
single oral administration of GT-Tal 
Pharmaco-
kinetic
parameters*
Units
Compounds
Free GT
Conjugated 
GT
Conjugated 
GT-Tal
λz 1/h 0.22 ± 0.01 0.19 ± 0.02 0.15 ± 0.01
t1/2λZ h 3.20 ± 0.81 3.63 ± 1.04 4.61 ± 1.57
Cmax μg/mL 0.24 ± 0.01 0.41 ± 0.25 2.74 ± 0.93
Tmax h 1.00 ± 0.00 0.69 ± 0.38 0.25 ± 0.00
AUC0-12 h h･μg/mL 1.23 ± 0.51 0.95 ± 0.04 16.62 ± 0.96
AUC0-∞ h･μg/mL 1.33 ± 0.58 1.04 ± 0.04 20.15 ± 0.85
MRT h 4.69 ± 0.82 4.42 ± 0.39 6.89 ± 0.73
*Parameter definitions are the same as those in Table 1.
Discussion
The structure of GT-Tal, a newly identified isoflavonol 
glycoside, is similar to that of GT-Glu [7,22]. Consequently, 
we observed many differences in the pharmacokinetic 
profiles of GT-Tal and GT-Glu. GT-Glu was quickly 
hydrolyzed into its corresponding aglycon, GT, by 
α-glucosidase, β-glucosidase, β-glucuronidase/sulfatase, 
and sulfatase. However, GT-Tal was not hydrolyzed to GT 
by these enzymes. Hydrolytic enzymes may not recognize 
the alpha linkage between GT and talopyranose because 
6-deoxy-L-talose, a stereoisomer at C-4 of L-rhamnose, 
was characterized as an unusual sugar and has been found 
a residue of outer membrane lipopolysaccharides in some 
Gram-negative bacteria such as Escherichia coli, Aeromonas 
hydrophila, and Actinobacillus actinomycetemcomitans 
[8,13,19]. 
GT-Tal was rapidly absorbed through the gastrointestinal 
tract and rapidly metabolized into its conjugates and 
aglycone. The rapid absorption of GT-Tal may be due to 
differences in the specificity of the glycoside. This finding 
coincides with the report by Hollman et al. showing that 
the nature of the sugar group affects absorption of 
quercetin, a major flavonoid [6]. In this study, the majority 
of absorbed GT-Tal was quickly metabolized into its 
conjugates while a small amount of absorbed GT-Tal was 
degraded into its aglycone and conjugates. However, GT- 
Glu was quickly metabolized to the corresponding less 
polar aglycone, GT, prior to gastrointestinal absorption and 
was partly absorbed without previous cleavage.
The difference between GT-Tal and GT-Glu absorption 
and metabolism rates could be explained by the enzymatic 
hydrolysis of GT-Glu or GT-Tal. GT-Glu was slowly absorbed 
and then converted into its aglycone and conjugates. A 
small amount of GT-Glu was briefly present as an intact 
molecule in the portal vein circulation while GT derived 
from GT-Glu would be rapidly absorbed throughout the 
intestinal tract after oral intake [1,2,17,21]. The slow 
absorption of GT-Glu compared to that of GT-Tal may be 
because GT-Glu degradation by gastric hydrochloric acid, 
β-glycosidase present in the jejunum and ileum, and 
enterobacteria in the colon requires many steps [1,2,9]. 
It is noteworthy that the concentration of GT-Tal 
conjugates was higher than that of its GT conjugates long 
after oral administration. Despite numerous reports of 
flavonoid glycoside hydrolysis by intestinal microflora 
and brush border enzymes [3,11,21] and of glycoside 
uptake by an intestinal glucose transporters [20], it is still 
unclear whether or not flavonoid glycosides are absorbed 
in the intestine of rats in vivo. However, some studies have 
reported that flavonoids might be absorbed in their 
glycosylated form via intestinal sugar carriers, whereas the 
oral absorption of many isoflavonic glycosides was shown 
to be inhibited due to isoflavone degradation by gastric 
acid and β-glycosidase present in the jejunum and ileum 
[6,9,14,16]. It was speculated that intestinal sugar carriers 
may play a role in GT-Tal absorption and slow conversion 
into its aglycone. 
In conclusion, a number of differences in the absorption 
and metabolism of GT-Tal and GT-Glu were observed due 
to their different sugar moiety. GT-Tal was metabolized 
into its corresponding conjugates or underwent 
deglycosylation to produce GT. In contrast, GT-Glu was 
metabolized into its aglycone, GT. The pharmacodynamic 
effect of the GT-Tal metabolites detected in our study is 
still unclear. Thus, the in vitro activities of free GT-Tal 
cannot be directly transferred to in vivo conditions. Further 
studies are required to demonstrate whether the 
conjugative metabolites of GT-Tal possess some biological 
activities that may enable them to serve as an important 
source of cellular aglycones upon enzymatic hydrolysis at 
the target site.
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